The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) hit a new 52-week low and has $13.98 target or 7.00% below today’s $15.03 share price. The 8 months bearish chart indicates high risk for the $5.11B company. The 1-year low was reported on Nov, 8 by Barchart.com. If the $13.98 price target is reached, the company will be worth $357.70 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 50.36M shares traded hands or 200.48% up from the average. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 33.24% since April 5, 2016 and is downtrending. It has underperformed by 35.20% the S&P500.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 75 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. Canaccord Genuity maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, March 16. Canaccord Genuity has “Hold” rating and $40 price target. The rating was maintained by Jefferies on Monday, November 2 with “Buy”. The company was maintained on Tuesday, August 9 by Rodman & Renshaw. The rating was initiated by Rodman & Renshaw on Tuesday, February 16 with “Buy”. RBC Capital Markets maintained the shares of VRX in a report on Tuesday, October 27 with “Outperform” rating. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Overweight” rating by JP Morgan on Wednesday, November 11. As per Tuesday, October 20, the company rating was maintained by Scotia Capital. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Buy” rating given on Friday, November 20 by Mizuho. The firm has “Hold” rating by Deutsche Bank given on Tuesday, October 20.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.06, from 0.92 in 2016Q1. The ratio dived, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Reilly Advsr Limited Co has 0% invested in the company for 70 shares. Shell Asset Mngmt has 43,020 shares for 0.03% of their US portfolio. Moreover, Stanley Mngmt Ltd Co has 1.17% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 57,800 shares. Eagle Capital Lc last reported 0% of its portfolio in the stock. Commonwealth Equity Svcs has invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Jackson Park Capital Limited Liability accumulated 0.58% or 21,000 shares. The Minnesota-based Ameriprise Fincl has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Moreover, Sg Americas Ltd has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 21,687 shares. Prudential Public Ltd Com accumulated 0.01% or 75,000 shares. The Netherlands-based Apg Asset Management Nv has invested 0.03% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). First New York Secs Ltd Ny reported 5,100 shares or 0% of all its holdings. Teewinot Capital Advisers Lc last reported 0.83% of its portfolio in the stock. Sector Pension Investment Board last reported 506,617 shares in the company. City Holdings accumulated 525 shares or 0% of the stock. Raymond James Service Advisors last reported 12,107 shares in the company.
Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 insider sales for $5.04 million net activity. PAPA JOSEPH C had bought 202,000 shares worth $4.94M. 4,000 shares were bought by KARABELAS ARGERIS N, worth $98,600 on Thursday, August 11.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Fool.com with their article: “Another Month, Another 27% Decline for Valeant Pharmaceuticals Intl. Inc. in …” published on November 07, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: CVS Health Corp, Valeant Pharmaceuticals Intl Inc, and Facebook Inc” with publication date: November 08, 2016.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.